Pharvaris (NASDAQ:PHVS) Short Interest Up 24.7% in February

Pharvaris (NASDAQ:PHVS) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 487,300 shares, a growth of 24.7% from the February 13th total of 390,900 shares. Based on an average daily volume of 55,500 shares, the short-interest ratio is currently 8.8 days. Approximately 2.8% of the company’s shares are short sold.

Pharvaris Stock Down 0.0 %

Pharvaris stock traded down $0.01 during trading hours on Monday, hitting $16.67. The stock had a trading volume of 26,051 shares, compared to its average volume of 70,830. The stock has a market capitalization of $871.41 million, a P/E ratio of -5.94 and a beta of -3.02. Pharvaris has a 12-month low of $14.14 and a 12-month high of $26.57. The stock’s 50-day moving average price is $17.13 and its 200-day moving average price is $19.13.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of Pharvaris in the third quarter worth about $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Pharvaris during the third quarter valued at approximately $906,000. State Street Corp purchased a new position in shares of Pharvaris in the third quarter worth $1,000,000. Geode Capital Management LLC boosted its position in shares of Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after acquiring an additional 5,753 shares during the last quarter. Finally, Barclays PLC purchased a new position in Pharvaris during the third quarter valued at $106,000.

Analyst Ratings Changes

Separately, JMP Securities upped their price target on Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research report on Friday, January 31st.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.